Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb;52(1):81-85.
doi: 10.5152/eurasianjmed.2020.19218.

Current Pharmacological Approach to ARDS: The Place of Bosentan

Omer Araz  1
Affiliations
Review

Current Pharmacological Approach to ARDS: The Place of Bosentan

Omer Araz. Eurasian J Med. 2020 Feb.

Abstract

Acute respiratory distress syndrome is characterized by dyspnea at presentation, tachypnea on physical examination, findings of bilateral infiltration in chest radiography, refractory hypoxia, and high mortality. Although the main treatment approach is to address the underlying disease, there are also pharmacological and nonpharmacological options for supportive treatment. There is currently no pharmacological agent with proven efficacy in this syndrome, and many drugs are being studied for this purpose. One of these is the endothelin receptor antagonist bosentan.

Keywords: ARDS; bosentan; pharmacological treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Appearance of normal lung (H&E, ×100).
Figure 2. a–d
Figure 2. a–d
Appearance of a lung with ARDS: (a) hemorrhage (arrowhead), terminal bronchiole (arrow) (H&E, ×100); (b) thickening of the interalveolar septa (arrowhead), alveolar filling defects (H&E, ×100); (c) PNL infiltration (arrowhead), MNL infiltration (arrow) (H&E, ×200); (d) vasodilation–congestion (arrowhead), terminal bronchiole (arrow) (H&E, ×100).
Figure 3. a, b
Figure 3. a, b
Appearance after treatment with 100 mg/kg bosentan: (a) ias, interalveolar septum; Tb, terminal bronchiole (H&E, ×100); (b) (H&E, ×200).
See this image and copyright information in PMC

References

    1. Thompson BT, Chambers RC, Liu KD. Acute Respiratory Distress Syndrome. N Engl J Med. 2017;377:562–72. doi: 10.1056/NEJMra1608077. - DOI - PubMed
    1. Aggarwal NR, King LS, D’Alessio FR. Diverse macrophage populations mediate acute lung inflammation and resolution. Am J Physiol Lung Cell Mol Physiol. 2014;306:L709–25. doi: 10.1152/ajplung.00341.2013. - DOI - PMC - PubMed
    1. Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016;315:788. doi: 10.1001/jama.2016.0291. - DOI - PubMed
    1. The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354:1671–84. doi: 10.1056/NEJMoa051693. - DOI - PubMed
    1. Pham T, Serpa Neto A, Pelosi P, et al. Outcomes of Patients Presenting with Mild Acute Respiratory Distress Syndrome: Insights from the LUNG SAFE Study. Anesthesiology. 2019;130:263–83. doi: 10.1097/ALN.0000000000002508. - DOI - PubMed

LinkOut - more resources